No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases

Neurobiology of Disease

Volumn 35, Issue 2, 2009, Pages 296-301

  Maetzler, Walter ^a,b   Keller, Stefanie ^a   Michelis, Joan ^a   Koehler, Niklas ^c   Stransky, Elke ^c   Becker, Clemens ^b   Schulte, Claudia ^a   Melms, Arthur ^a   Gasser, Thomas ^a   Berg, Daniela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

BChE K variant; Butyrylcholinesterase; Cholinesterase inhibitors; Dementia with Lewy bodies; Lewy body disease; Parkinson's disease dementia

Indexed keywords

ACETYLCHOLINE; AMYLOID; APOLIPOPROTEIN E4; CHOLINESTERASE;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROCHEMISTRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; AGING; APOLIPOPROTEIN E4; BUTYRYLCHOLINESTERASE; COGNITION; COGNITION DISORDERS; ENZYMES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; SEQUENCE ANALYSIS, DNA; SEX CHARACTERISTICS;

EID: 67649491056     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.05.014     Document Type: Article

References (36)

1. Aarsland D., et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60 (2003) 387-392
2. Altamirano C.V., et al. The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme. J. Neurochem. 74 (2000) 869-877
3. Apaydin H., et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59 (2002) 102-112
4. Atack J.R., et al. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J. Neurochem. 47 (1986) 263-277
5. Ballard C.G. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur. Neurol. 47 (2002) 64-70
6. Bartels C.F., et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am. J. Hum. Genet. 50 (1992) 1086-1103
7. Bohnen N.I., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 60 (2003) 1745-1748
8. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24 (2003) 197-211
9. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
10. Cummings J.L. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J. Geriatr. Psychiatry. Neurol. 1 (1988) 24-36
11. Darreh-Shori T., et al. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol. Dis. 24 2 (2006) 326-333
12. Darvesh S., et al. Butyrylcholinesterase-mediated enhancement of the enzymatic activity of trypsin. Cell. Mol. Neurobiol. 21 (2001) 285-296
13. Darvesh S., et al. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 4 (2003) 131-138
14. Diamant S., et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8628-8633
15. Ellman G.L., et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
16. Emre M., et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351 (2004) 2509-2518
17. Gibb W.R., and Lees A.J. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 38 (1988) 1402-1406
18. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
19. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid. Res. 31 (1990) 545-548
20. Holmes C., et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J. Neurol. Neurosurg. Psychiatry. 76 (2005) 640-643
21. Lane R., et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet. Genomics 18 (2008) 289-298
22. Lane R., et al. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov. Disord. 24 (2009) 392-400
23. Leech R.W., et al. Dementia: the University of Oklahoma autopsy experience. J. Okla. State Med. Assoc. 94 (2001) 507-511
24. Lehmann D.J., et al. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum. Genet. 106 (2000) 447-452
25. Lippa C.F., et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68 (2007) 812-819
26. Mattila K.M., et al. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. J. Med. Genet. 37 (2000) 766-770
27. McKeith I.G., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
28. Mesulam M.M., and Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 36 (1994) 722-727
29. Perry E.K., et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 4 (1978) 273-277
30. Perry E., et al. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 60 (2003) 1852-1853
31. Podoly E., et al. Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener. Dis. 5 (2008) 232-236
32. Poewe W., et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov. Disord. 21 (2006) 456-461
33. Singleton A.B., et al. Butyrylcholinesterase K: an association with dementia with Lewy bodies. Lancet 351 (1998) 1818
34. Tilley L., et al. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Eur. J. Hum. Genet. 7 (1999) 659-663
35. Tiraboschi P., et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54 (2000) 407-411
36. Trojanowski J.Q., and Lee V.M. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann. N. Y. Acad. Sci. 991 (2003) 107-110